Cargando…

Saliva metabolomic profile of COVID-19 patients associates with disease severity

INTRODUCTION: Coronavirus disease 2019 (COVID-19) is strongly linked to dysregulation of various molecular, cellular, and physiological processes that change abundance of different biomolecules including metabolites that may be ultimately used as biomarkers for disease progression and severity. It i...

Descripción completa

Detalles Bibliográficos
Autores principales: Saheb Sharif-Askari, Narjes, Soares, Nelson Cruz, Mohamed, Hajer A., Saheb Sharif-Askari, Fatemeh, Alsayed, Hawra Ali Hussain, Al-Hroub, Hamza, Salameh, Laila, Osman, Rufaida Satti, Mahboub, Bassam, Hamid, Qutayba, Semreen, Mohammad H., Halwani, Rabih
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589589/
https://www.ncbi.nlm.nih.gov/pubmed/36271948
http://dx.doi.org/10.1007/s11306-022-01936-1
_version_ 1784814337297219584
author Saheb Sharif-Askari, Narjes
Soares, Nelson Cruz
Mohamed, Hajer A.
Saheb Sharif-Askari, Fatemeh
Alsayed, Hawra Ali Hussain
Al-Hroub, Hamza
Salameh, Laila
Osman, Rufaida Satti
Mahboub, Bassam
Hamid, Qutayba
Semreen, Mohammad H.
Halwani, Rabih
author_facet Saheb Sharif-Askari, Narjes
Soares, Nelson Cruz
Mohamed, Hajer A.
Saheb Sharif-Askari, Fatemeh
Alsayed, Hawra Ali Hussain
Al-Hroub, Hamza
Salameh, Laila
Osman, Rufaida Satti
Mahboub, Bassam
Hamid, Qutayba
Semreen, Mohammad H.
Halwani, Rabih
author_sort Saheb Sharif-Askari, Narjes
collection PubMed
description INTRODUCTION: Coronavirus disease 2019 (COVID-19) is strongly linked to dysregulation of various molecular, cellular, and physiological processes that change abundance of different biomolecules including metabolites that may be ultimately used as biomarkers for disease progression and severity. It is important at early stage to readily distinguish those patients that are likely to progress to moderate and severe stages. OBJECTIVES: This study aimed to investigate the utility of saliva and plasma metabolomic profiles as a potential parameter for risk stratifying COVID-19 patients. METHOD: LC–MS/MS-based untargeted metabolomics were used to profile the changes in saliva and plasma metabolomic profiles of COVID-19 patients with different severities. RESULTS: Saliva and plasma metabolites were screened in 62 COVID-19 patients and 18 non-infected controls. The COVID-19 group included 16 severe, 15 moderate, 16 mild, and 15 asymptomatic cases. Thirty-six differential metabolites were detected in COVID-19 versus control comparisons. SARS-CoV-2 induced metabolic derangement differed with infection severity. The metabolic changes were identified in saliva and plasma, however, saliva showed higher intensity of metabolic changes. Levels of saliva metabolites such as sphingosine and kynurenine were significantly different between COVID-19 infected and non-infected individuals; while linoleic acid and Alpha-ketoisovaleric acid were specifically increased in severe compared to non-severe patients. As expected, the two prognostic biomarkers of C-reactive protein and D-dimer were negatively correlated with sphingosine and 5-Aminolevulinic acid, and positively correlated with l-Tryptophan and l-Kynurenine. CONCLUSION: Saliva disease-specific and severity-specific metabolite could be employed as potential COVID-19 diagnostic and prognostic biomarkers. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11306-022-01936-1.
format Online
Article
Text
id pubmed-9589589
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-95895892022-10-24 Saliva metabolomic profile of COVID-19 patients associates with disease severity Saheb Sharif-Askari, Narjes Soares, Nelson Cruz Mohamed, Hajer A. Saheb Sharif-Askari, Fatemeh Alsayed, Hawra Ali Hussain Al-Hroub, Hamza Salameh, Laila Osman, Rufaida Satti Mahboub, Bassam Hamid, Qutayba Semreen, Mohammad H. Halwani, Rabih Metabolomics Original Article INTRODUCTION: Coronavirus disease 2019 (COVID-19) is strongly linked to dysregulation of various molecular, cellular, and physiological processes that change abundance of different biomolecules including metabolites that may be ultimately used as biomarkers for disease progression and severity. It is important at early stage to readily distinguish those patients that are likely to progress to moderate and severe stages. OBJECTIVES: This study aimed to investigate the utility of saliva and plasma metabolomic profiles as a potential parameter for risk stratifying COVID-19 patients. METHOD: LC–MS/MS-based untargeted metabolomics were used to profile the changes in saliva and plasma metabolomic profiles of COVID-19 patients with different severities. RESULTS: Saliva and plasma metabolites were screened in 62 COVID-19 patients and 18 non-infected controls. The COVID-19 group included 16 severe, 15 moderate, 16 mild, and 15 asymptomatic cases. Thirty-six differential metabolites were detected in COVID-19 versus control comparisons. SARS-CoV-2 induced metabolic derangement differed with infection severity. The metabolic changes were identified in saliva and plasma, however, saliva showed higher intensity of metabolic changes. Levels of saliva metabolites such as sphingosine and kynurenine were significantly different between COVID-19 infected and non-infected individuals; while linoleic acid and Alpha-ketoisovaleric acid were specifically increased in severe compared to non-severe patients. As expected, the two prognostic biomarkers of C-reactive protein and D-dimer were negatively correlated with sphingosine and 5-Aminolevulinic acid, and positively correlated with l-Tryptophan and l-Kynurenine. CONCLUSION: Saliva disease-specific and severity-specific metabolite could be employed as potential COVID-19 diagnostic and prognostic biomarkers. GRAPHICAL ABSTRACT: [Image: see text] SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1007/s11306-022-01936-1. Springer US 2022-10-22 2022 /pmc/articles/PMC9589589/ /pubmed/36271948 http://dx.doi.org/10.1007/s11306-022-01936-1 Text en © The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature 2022, Springer Nature or its licensor holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law. This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Original Article
Saheb Sharif-Askari, Narjes
Soares, Nelson Cruz
Mohamed, Hajer A.
Saheb Sharif-Askari, Fatemeh
Alsayed, Hawra Ali Hussain
Al-Hroub, Hamza
Salameh, Laila
Osman, Rufaida Satti
Mahboub, Bassam
Hamid, Qutayba
Semreen, Mohammad H.
Halwani, Rabih
Saliva metabolomic profile of COVID-19 patients associates with disease severity
title Saliva metabolomic profile of COVID-19 patients associates with disease severity
title_full Saliva metabolomic profile of COVID-19 patients associates with disease severity
title_fullStr Saliva metabolomic profile of COVID-19 patients associates with disease severity
title_full_unstemmed Saliva metabolomic profile of COVID-19 patients associates with disease severity
title_short Saliva metabolomic profile of COVID-19 patients associates with disease severity
title_sort saliva metabolomic profile of covid-19 patients associates with disease severity
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9589589/
https://www.ncbi.nlm.nih.gov/pubmed/36271948
http://dx.doi.org/10.1007/s11306-022-01936-1
work_keys_str_mv AT sahebsharifaskarinarjes salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT soaresnelsoncruz salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT mohamedhajera salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT sahebsharifaskarifatemeh salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT alsayedhawraalihussain salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT alhroubhamza salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT salamehlaila salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT osmanrufaidasatti salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT mahboubbassam salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT hamidqutayba salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT semreenmohammadh salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity
AT halwanirabih salivametabolomicprofileofcovid19patientsassociateswithdiseaseseverity